Natera, Inc. (NASDAQ:NTRA) Receives $175.76 Average PT from Brokerages

Shares of Natera, Inc. (NASDAQ:NTRA) have received an average recommendation of “Buy” from the sixteen ratings firms that are currently covering the firm, Marketbeat.com reports. Sixteen equities research analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $175.76.

Several brokerages recently issued reports on NTRA. Piper Sandler increased their price objective on Natera from $200.00 to $205.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 4th. Sanford C. Bernstein increased their price target on Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, January 10th. Guggenheim lifted their price objective on Natera from $170.00 to $200.00 and gave the company a “buy” rating in a report on Friday, January 17th. StockNews.com upgraded shares of Natera from a “sell” rating to a “hold” rating in a report on Wednesday, March 19th. Finally, The Goldman Sachs Group boosted their price target on shares of Natera from $160.00 to $190.00 and gave the company a “buy” rating in a report on Tuesday, January 28th.

Natera Stock Performance

NASDAQ NTRA opened at $160.10 on Friday. Natera has a fifty-two week low of $92.14 and a fifty-two week high of $183.00. The company has a market cap of $21.64 billion, a P/E ratio of -90.97 and a beta of 1.79. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The business’s 50 day moving average price is $146.94 and its 200-day moving average price is $154.88.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.01. The firm had revenue of $476.10 million for the quarter, compared to the consensus estimate of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Sell-side analysts predict that Natera will post -1.49 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Steven Leonard Chapman sold 6,980 shares of the business’s stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $150.10, for a total transaction of $1,047,698.00. Following the transaction, the chief executive officer now directly owns 185,182 shares in the company, valued at $27,795,818.20. The trade was a 3.63 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Solomon Moshkevich sold 6,000 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $143.29, for a total value of $859,740.00. Following the completion of the sale, the insider now owns 143,768 shares of the company’s stock, valued at approximately $20,600,516.72. This trade represents a 4.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 152,436 shares of company stock valued at $22,019,079. 7.60% of the stock is currently owned by insiders.

Institutional Trading of Natera

Institutional investors have recently bought and sold shares of the stock. LRI Investments LLC purchased a new position in shares of Natera in the fourth quarter worth $29,000. Blue Trust Inc. increased its position in shares of Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 97 shares during the period. Rakuten Securities Inc. raised its stake in Natera by 117.8% in the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company’s stock worth $31,000 after acquiring an additional 119 shares during the last quarter. ORG Partners LLC acquired a new stake in Natera during the 1st quarter worth about $32,000. Finally, TCTC Holdings LLC grew its stake in Natera by 114.8% during the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 124 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.